• About Us
  • Add Post
  • Contact
  • Contribute For Us
  • Homepage
  • Our Authors
  • Privacy Policy
What's Hot

Pomerantz Law Firm Investigates Claims

March 21, 2023

Pomerantz Law Firm Investigates Claims

March 21, 2023

climate goals, circular economy and support to people & communities

March 21, 2023
What's Hot

Pomerantz Law Firm Investigates Claims

March 21, 2023

Pomerantz Law Firm Investigates Claims

March 21, 2023

climate goals, circular economy and support to people & communities

March 21, 2023
Facebook Twitter Instagram
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors
Facebook Twitter LinkedIn
BusinessLendBusinessLend
  • NEWS
  • BUSINESS
  • AUTO
  • TECH
  • MONEY
  • STARTUP
  • SUCCESS STORIES
  • OTHER
    • Press Release
    • OPINION
Subscribe
BusinessLendBusinessLend
Home»Press Release»Ventyx Biosciences Provides Update on Silicon Valley Bank
Press Release

Ventyx Biosciences Provides Update on Silicon Valley Bank

NewsVoirBy NewsVoirMarch 11, 2023No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email





ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver.

The majority of our cash and cash equivalents are held in accounts outside of SVB and our investment portfolio has no exposure to SVB. A portion of our cash is deposited in accounts with SVB and custodial accounts managed by SVB, and Ventyx may not have full access to these funds in the near-term. We do not see a material impact to our liquidity position or our ongoing operations as a result of this event.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Forward-Looking Statements

Ventyx cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Ventyx’s expectations regarding the impact of the SVB receivership on Ventyx’s liquidity position and operations. The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Ventyx’s business, including those risks described in Ventyx’s prior press releases and Ventyx’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of Ventyx’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed on November 4, 2022, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Ventyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
[email protected]

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
NewsVoir
  • Twitter

We are a leading corporate news distribution platform and we distribute high quality corporate and financial announcements for many large as well as upcoming brands from across India.

Related Posts

Pomerantz Law Firm Investigates Claims

March 21, 2023

Pomerantz Law Firm Investigates Claims

March 21, 2023
Add A Comment

Comments are closed.

Advertisement
Editors Picks

Leon Edwards vs Kamaru Usman LIVE: UFC 286 stream, newest updates and easy methods to watch tonight

March 18, 2023

Romain Grosjean’s Charred F1 Car Will Be Displayed at a Museum

February 21, 2023

The FBI Is Investigating a Cyberattack on Continental Tire

November 24, 2022

Lebanon’s banks to shut ‘indefinitely’ after heists by indignant depositors

September 22, 2022
Advertisement
Latest Posts

Pomerantz Law Firm Investigates Claims

March 21, 2023

Pomerantz Law Firm Investigates Claims

March 21, 2023

climate goals, circular economy and support to people & communities

March 21, 2023

Business Lend is a platform which brings executives officers, entrepreneurs, and venture capitalist together from different sectors. We keep on connecting with our users with the help of our monthly edition carving our way slowly towards the highest readership.

Facebook Twitter Instagram LinkedIn
Must Read
  • Pomerantz Law Firm Investigates Claims March 21, 2023
  • Pomerantz Law Firm Investigates Claims March 21, 2023
  • climate goals, circular economy and support to people & communities March 21, 2023

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2023 BusinessLend. Designed by ThemeSphere.
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors

Type above and press Enter to search. Press Esc to cancel.